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                             ABSTRACT 
Vein graft disease is a chronic inflammatory disease and limits the late results of coronary 
revascularization. Calcitonin gene-related peptide (CGRP) inhibits macrophages infiltrated and 
inflammatory mediators, we hypothesized that transfected CGRP gene inhibits macrophages 
infiltrated and inflammatory mediators in vein graft disease. Autologous rabbit jugular vein grafts 
were incubated ex vivo in a solution of mosaic adeno-associated virus vectors containing CGRP 
gene (AAV2/1.CGRP) 、escherichia coli lac Z gene (AAV2/1.LacZ) or saline and then interposed 
in the carotid artery. Intima/media ratio were evaluated at postoperative 4 weeks, Macrophages 
were marked with CD68 antibody by immunocytochemistry.Inflammatory mediators were 
mensurated with real-time PCR.Neointimal thickening was significantly suppressed in 
AAV2/1.CGRP group. Macrophages infiltrated and inflammatory mediators monocyte 
chemoattractant protein-1 (MCP-1)、tumor necrosis factorα(TNF-α)、inducible nitricoxide synthase 
(iNOS)、matrix metalloproteinase-9 (MMP-9) was significantly suppressed in AAV2/1.CGRP 
group. Gene transfected AAV2/1.CGRP suppressed neointimal hyperplasia in vein graft disease by 
suppressed macrophages infiltrated and inflammatory mediators. 







Autologous vein is usually using a material in artery rebuild,But, it was exposed to 
ischemia、trauma、inflammatory reaction and received high pressure and so on , embolism、spasm 
were appearred in early period, neointimal thickening and atherosclerosis were appearred in 
later,angioma occurred by chance,the phenomenon is vein graft disease.It is affected severely 
clinic effect of coronary artery bypass grafting （CABG）and peripheral vascular disease 
operation[1,2,3].Previous data shown that inflammatory cells infiltrated and inflammatory mediators 
released in the vein grafts, Macrophages and inflammatory mediators stimulated hyperplasia of 
vascular smooth muscle cells and neointimal thickening[4,5]. 
Calcitonin gene-related peptide（CGRP）is a 37-amino acid biological activity neuropeptide, 
The nerve contained CGRP wraped in larger part vascular[6,7]. Previous studies have shown that 
CGRP inhibits inflammatory cells and inflammatory mediators[8,9], protects endothelial 
function[10,11] and inhibits vascular smooth muscle cells hyperplasia[12,13].Accordingly, we sought 
to evaluate the effects of CGRP, using mosaic adeno-associated virus vectors gene transfer, on 


















1. Gene Expression in Vein Grafts 
Gene expression of an AAV2/1.CGRP at 4 weeks after infection and grafting was noted only in the 
AAV2/1.CGRP group vein grafts(Fig 1A). Both AAV2/1.CGRP group grafts and plasmid cDNA 
(positive control) yielded an identical cDNA product (227 bp), The AAV2/1.LacZ group and saline 
group and saline did not show CGRP RNA expression(Fig. 1A). 
Gene expression of an AAV2/1.LacZ at 4 weeks, processed with X-gal chromagen for 
β-galactosidase, demonstrates excellent gene transfer with AAV2/1.LacZ (Fig. 1B). Endogenous 
β-galactosidase activity was not detected in saline group and AAV2/1.CGRP group vein grafts. 
 
 
Fig. 1 Gene Expression in Vein Grafts . Fig. 1A.The expression of CGRP RNA at 4 weeks 
AAV2/1.CGRP group vein grafts. The total RNA extracted from AAV2/1.CGRP group, 
AAV2/1.LacZ group, and saline group vein grafts. AAV2/1.CGRP as postive control,Saline as 
negative control. AAV2/1.CGRP group and AAV2/1.CGRP are depicted here with positive. 
PCR cDNA products are visualized on agarose gels stained with ethidium bromide. Fig. 1B, 
Cross-sectional view of an AAV2/1.lac Z group vein grafts. Dark blue inclusions demonstrate 
β-galactosidase staining (original magnification, ×200). 
2. CGRP Reduces Vein Graft Disease in rabbits 
The intimal and medial area in EVG-stained cross sections was measured at 4 weeks(Fig. 2A). 
AAV2/1.CGRP group significantly suppressed intimal hyperplasia as compared to AAV2/1.LacZ 
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group and saline group (37% and 39% less, respectively; P<0.001, Fig. 2B). Moreover, the 
anti-inflammatory effect of CGRP, as infiltration of macrophages into the graft wall is also 
considered to play an important role in the response to vein graft disease. Immunohistochemical 
study demonstrated that infiltration of macrophages was markedly increased in specimens in 
AAV2/1.LacZ group or Saline group, while recruitment of macrophages was significantly inhibited 
by transfection of AAV2/1.CGRP(Fig. 3). 
 
Fig. 2 Effect of transfection of CGRP on neointimal hyperplasia in vein graft at 4 weeks after 
surgery. Fig.2A.Representative histological sections of vein graft stained with elastic van Gieson's 
stain (magnification×100). Fig. 2B.Intimal and medial area in cross-sections and ratio of intimal to 




Fig. 3 Histopathological and immunohistochemical studies findings in rabbit vein grafts. In 
AAV2/1.CGRP group vein grafts, The muscularis and intima are intact; In AAV2/1.LacZ  group and 
Saline group,the intima hyperplasia or untill complete occlusion﹙Fig. 3A﹚. In AAV2/1.CGRP group vein 
grafts, There is minimal inflammation; But In AAV2/1.LacZ group and saline group, inflammatory cells 
infiltrated all layers of the vein grafts﹙Fig. 3B﹚. Immunohistochemical studies with a monoclonal 
antibody CD68 specific for macrophages demonstrated minimal macrophages immunostaining was 
noted in AAV2/1.CGRP group vein graftss; high-level expression of macrophages in the endothelium 






3. Inflammation Mediating Molecules mRNA Expression 
Expression levels of inflammation mediating molecules in vein graft samples of all rabbit groups 
were higher than those of AAV2/1.CGRP group (Fig. 4). The AAV2/1.CGRP gene transfection 
significantly inhibited inflammation mediating molecules MCP-1、TNF-α、iNOS 、MMP-9 mRNA 
in vein grafts. The most significantly up-regulated inflammation mediating molecules mRNA was 
MMP-9, which displayed higher mRNA levels in the AAV2/1.LacZ group and saline group 
controls. 
 
Fig. 4 Mean inflammation-mediating molecules mRNA levels in the vein grafts. All vein grafts 
were tested for inflammation mediating molecules mRNA levels by quantitative real-time PCR using 
GAPDH as internal standard. Each specific inflammation mediating molecules is indicated on the 







In the past, Kilian et al[15] showed transfected native rabbit jugular veins with recombinant 
AAV vector,Moreover, low immunogenicity of AAV may also allow long-term transgene 
expression; Sen et al[16] showed that AAV1 have advantages over AAV2 for vascular gene delivery 
at low titres; Stachler et al[17] showed that mosaic AAV1 particles in a 50-100-fold enhancement in 
endothelial cell gene transfer and suggest that mosaic virions hold significant promise for targeted 
gene delivery to the vasculature.In the present study we showed that recombinant mosaic AAV2/1 
facilitates an effective gene transfection in an autologous rabbit vein grafts model. Our data have 
shown that AAV2/1.CGRP was transfected effectively to vein grafts(Fig. 1),AAV2/1 gene transfer 
of CGRP significantly reduced the ratio of intimal to medial area(Fig. 2) and dramatically reduced 
macrophage recruitment(Fig. 3) in vein grafts at 4 weeks after surgery.Our genic transfection 
means is a specific interest for the surgical perspective,Because the preparation and instillation of 
the viral solution can be performed easily in a bypass operation(Fig. 5). 
MCP-1 is a potent monocyte chemotactic and activating factor belonging to the C-C family 
of intercrine cytokines,which is synthesized by endothelial cells, smooth muscle cells, fibroblasts, 
and monocytes/ macrophages, all of which are present in vein grafts[18,19]. Upregulation of MCP-1 
gene expression in vein grafts results in the recruitment of monocytes and tissue macrophages to 
the vein wall, which leads to intimal hyperplasia (IH). The correlation between monocyte/ 
macrophage infiltration and IH suggests a critical role for these cells in IH development[19,20]. 
Previous studies have shown anti-MCP-1 gene therapy inhibits vascular smooth muscle cells 
proliferation and attenuates vein graft thickening both in vitro and in vivo[21,22,23]. Li et al[8]report 
intrinsic and extrinsic peptide CGRP inhibits IL-1 -induced MCP-1 secretion in an 
autocrine/paracrine mode and suppresses the IL-1 -evoked ROS-NF- B cascade via cAMP 
signaling. It is also known that CGRP suppressed the number of macrophage colonies formed[24]. 
In the present study, Our data shown that AAV2/1.CGRP-treated suppressed MCP-1 mRNA and 
macrophage(Fig. 3, Fig. 4A), It is possible mechanism that CGRP-treated vein graft disease by 
suppressed MCP-1 and macrophages. 
Macrophages express inducible nitric oxide synthase (iNOS) and tumour necrosis factor 
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alpha (TNF-α) and multiple metalloproteinases[4,25,26]，A number of previous studies have 
suggested that an essential role for MMP-9 activation in the development of vascular SMC 
proliferation, migration and neointima formation[27,28]. TNF-α-induced MMP-9 production and 
promoter activity[29], effectively suppresses TNF-alpha-induced VSMC migration through the 
selective inhibition of MMP-9 expression[30,31]. Likewise, iNOS increase the expression of matrix 
metalloproteinase-9 in vascular smooth muscle, iNOS is related with the development of 
atherosclerosis[32,33,34].TNF- α and iNOS generated by macrophages can be inhibited by 
CGRP[35,36].Our study shown that CGRP inhibit macrophages infiltration and inflammation 
mediating molecules TNF-αand iNOS, especially MMP-9(Fig. 3, Fig. 4B、C、D),Accordingly,We 
deduced that the macrophages and inflammation mediating molecules are played an essential role 
in the development vein graft disease, CGRP suppresses vein graft disease by inhibits macrophages 
infiltration and inflammation mediating molecules. 
In conclusion, Our study demonstrated that AAV2/1.CGRP gene transfer via ex vivo 
inhibited macrophage infiltration and inflammation mediating molecules mRNA of MCP-1、TNF-
α、iNOS and MMP-9,dramatically reduced vessel wall thickening in vein graft disease. These 
findings highlight the importance of AAV2/1.CGRP gene transfer in clinic treatment vein graft 
disease. 
Materials and methods 
1.Rabbit Vein Graft Model and ex Vivo Gene Transfer 
25 Adult male New Zealand white rabbits (2.5～3.0kg) were anesthetized with an 
intramuscular injection of pentobarbital (3mg/kg; sigma), Neither mechanical ventilation nor 
supplemental intravenous fluid administration was required. Under general anesthesia and using a 
sterile technique, the right jugular vein and carotid artery were exposed through a midline incision. 
An approximately 3.0 cm segment of the jugular vein, lacking valves, was isolated by ligation of 
the proximal and distal vein for the autologous reversed-vein graft. A small venotomy was made in 
the distal vein. About a 300μL volume of  AAV2/1.CGRP(at 5×1010vg/ml, n=8), AAV2/1.LacZ 
(at 5×1010vg/ml, n=9) or Saline (n=8) was injected into the lumen of the isolated vein and 
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maintained expanded.Then resected the segment of the jugular vein and put it into a tube contained 
2ml AAV2/1.CGRP(at 5×1010vg/ml) or AAV2/1.LacZ(at 5×1010vg/ml) or Saline in 30 minutes at 
room temperature（Fig 5）. 
After systemic heparinization (1000 IU), the ipsilateral common carotid artery was dissected 
and clamped. End-to-side interpositional grafting of the jugular vein segment to the carotid artery 
was performed using 9-0 nylon continuous running suture. Arterial blood flow was restored to the 
carotid artery and vein graft. The neck incision was closed, and the animals were placed under a 
warming light until fully recovered from anesthesia. After recovery, the rabbits were maintained on 
a light-dark (12-12 hour) cycle at 24° C and fed a normal diet and water as desired. Antibiotic 
prophylaxis was provided with penicillin 4×105U intramuscularly 2 times daily in 3 days. Animal 
care complied with the principles of laboratory animal care (China requirements of environment 
and housing facilities for laboratory animals,GB/T 14925-94; China  laboratory animals- rabbits 
formula feeds, GB 14924.4-2001).  
            
                  Fig. 5 The method of gene transfection 
2.Harvest and Processing of Tissue Samples 
The AAV2/1.CGRP group 、AAV2/1.LacZ group and Saline group dyed 1、2、1 rabbits within 4 
weeks, Dead rate is 16﹪(4/25). After induction of anesthesia and after confirming patency of the 
vessels studied, animals were euthanized with an overdose of anesthetic. Vein grafts harvested at 4 
weeks (n=7 per group), A 2.5mm long middle segment of vein grafts(n=7 per group) was fixed 
with 10% neutral-buffered formalin to do histological study; A 2.5mm long middle segment of 
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vein grafts(n=2 per group) and residual vein grafts(n=7 per group) were immediately snap-frozen 
with liquid nitrogen, then stored at －70°C for later study. 
3.Histological Study 
The fixed in 10% neutral buffered formalin vein grafts processed for routine paraffin embedding. 
Two sections were taken from the midportion of the vein grafts. Cross-sections (5 μm) were 
stained with both hematoxylin and eosin (HE) and elastic van Gieson's stain (EVG) in a standard 
manner. Intimal and medial areas were calculated by quantitative morphometric analysis with a 
computerized sketching program. The ratio of intimal to medial area was also calculated. 
4. X-gal Staining  
β-Galactosidase, an index of successful AAV1∕2.lacZ infection, was documented with X-gal 
chromagen in specimens,2 Samples AAV2/1.CGRP group and 2 samples saline group as negative 
controll. 6 Samples tissue samples were taken from -80℃ refrigeratory, Whole tissue X-gal 
chromagen staining was done according to exponent（GENMED）, a segment of vein was also 
fixed in 10% formalin and embedded in paraffin after X-gal chromagen staining. 8μm-thick cross 
section samples were cut from the paraffin blocks, then observed at ×400 magnification for 
evidence of production of β-galactosidase. Tissue cell stained positive for β-galactosidase is blue. 
5. Immunohistochemical Study 
Paraffin-embedded vein graft sections were stained for macrophage using a mouse monoclonal 
anti–CD68 antibody (Dako),For negative control experiments, the primary antibody was omitted. 
Immunohistochemical staining was performed using the immunoperoxidase avidin–biotin complex 
system. Then, 5- μ m sections were deparaffinized, rehydrated before blocking endogenous 
peroxidase activity with 3% hydrogen peroxidase and preincubated with 5% normal horse serum in 
sodium phosphate-buffered saline (PBS) for 30 min. Diluted primary antibodies (1:30) were then 
applied to the sections, and these sections were incubated overnight at 4 °C. With intervening 
washing in PBS, they were serially incubated with biotinylated anti-mouse IgG  in PBS and 
avidin-biotinylated horseradish peroxidase complex in PBS for 30 min, Immune complexes were 
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localized using 0.05% 3,3 ′ -diaminobenzidine (DAB), and slides were counterstained with 
hematoxylin. 
6. Reverse Transcription–Polymerase Chain Reaction of CGRP 
Total RNA was isolated from rabbit vein graft tissues by use of Trizol reagent (Invitrogen), then 
reverse-transcribed using a one-step reverse transcription–polymerase chain reaction (RT-PCR) kit 
(Invitrogen) with oligo(dT) primers. Then, the sequence of CGRP was amplified by PCR 
(annealing at 58°C for 45 seconds, extension at 72°C for 1minute, 30 cycles), The CGRP primers 
refer to table1. Also, Glyceraldehyde-3- phosphate dehydrogenase (GAPDH) (The primers design 
was refered data of Zucker ,et al[14]) was amplified as a reference use of a primer pair specific to 
rabbit GAPDH at the same reaction condition for 30 cycles.  
7.Real-Time Polymerase Chain Reaction 
RT-PCR reactions were performed on all rabbits’ mRNA at the same time for each individual 
inflammation-mediating molecules tested. First-strand cDNA synthesis was performed from 1.3μg 
of total RNA in 20 μL volumes with oligo(dT) priming, using Superscript First-strand Synthesis 
System (Invitrogen). PCR amplification was performed with Power SYBR Green PCR Master Mix 
(ABI),The molecules primers refer to table1.The reaction was incubated at 50°C for 2 minutes, 
95°C for 10 minutes, followed by 40 cycles of 15 seconds at 95°C, 1 minute at 60°C with use of a 
ABI 7000 sequence detection system. In all assays, the specificity of the final amplified products 
was verified by heat dissociation curve analysis with the use of software supplied by the 
manufacturer. 
Table 1. Primers Used for Inflammation-Mediating Molecules mRNA Assessment 
 Molecules     Sequence(5′-3′) PCR product size  (base pairs) 
   CGRP ATGGGCTTCCAAAAGTTCTCC 
CTGGAGCCCTCTCTCTCTTG 
   227 
   iNOS CTGCTTTGTGCGGAGTG 
CACCCGAACACCAGGAT 
174 
   TNF-α GGCTCAGAATCAGACCTCAG GCTCCACATTGCAGAGAAGA    297 
   MCP-1 CCAGCCAGATGCCGTGAAT 
AGATCCCCTTGGCCAGTTTG 
   155 
MMP-9 GCAGGGTAGGGGGTATGGA 630 
 12
ACAGGGCTTGGCTTTGGA 
   GADPH TCACCATCTTCCAGGAGCGA 
CACAATGCCGAAGTGGTCGT 
   293 
8.Statistical Analysis 
All results are expressed as mean±SEM. One-way ANOVA was used to compare differences 
between groups. A value of P＜0.05 was considered to indicate a statistically significant difference, 
with Bonferroni correction for multiple comparisons. 
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Table 1. Primers Used for Inflammation-Mediating Molecules mRNA Assessment 
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   CGRP ATGGGCTTCCAAAAGTTCTCC 
CTGGAGCCCTCTCTCTCTTG 
   227 
   iNOS CTGCTTTGTGCGGAGTG 
CACCCGAACACCAGGAT 
174 
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